Abu Dhabi Global Healthcare Week Partners with Digital Health New York to Boost Digital Health Ecosystem

By HEOR Staff Writer

October 8, 2023

Unifying Efforts for Digital Health Ecosystem Globally

Abu Dhabi Global Healthcare Week (ADGHW) has partnered with Digital Health New York (DHNY) to enhance the global digital health ecosystem. The Memorandum of Understanding (MoU), signed on October 4, 2023, aims to promote collaboration, innovation, long-term investment, and knowledge exchange in the digital health sector.

The two-year partnership will focus on developing research and innovation in digital health, enhancing credibility in science, and providing access to subject-matter experts through open dialogue.

Tackling Global Healthcare Challenges through Digital Tools

The partnership comes at a time when global healthcare demands require collaboration and access to digital tools. Both ADGHW and DHNY are committed to supporting ongoing research and development initiatives, particularly in genomics, preventative and predictive medicine.

H.E. Dr. Ahmed Alkhazraji, Executive Director, Strategy and Policy at the Department of Health – Abu Dhabi and Bunny Ellerin, Co-Founder & CEO, DHNY, signed the partnership. The collaboration aims to leverage both parties’ rich networks to access long-term investment and forge partnerships in the global digital health arena.

ADGHW and DHNY also emphasise the importance of scientific credibility in the healthcare industry and are joining forces in collaborative research studies and the creation of scientific literature.

Reference url

Recent Posts

CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Reductions

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this CRISPR-Cas9 gene-editing therapy...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adult NF1 Patients

By HEOR Staff Writer

November 7, 2025

European Commission Approves Koselugo for Adult NF1 Patients The European Commission has granted approval for Koselugo (selumetinib), an oral MEK inhibitor developed by Alexion, AstraZeneca Rare Disease, to treat symptomatic, inoperable plexiform neurofibromas in adult patients with neu...
Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss Potential
Are you wondering about the latest eloralintide obesity treatment options? Eloralintide, a selective amylin receptor agonist, has shown promising results in managing obesity. In a recent phase 2 trial, it led to significant weight loss of up to 20% over 48 weeks in adults with obesity or overweig...